skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 26,709  for All Library Resources

Results 1 2 3 4 5 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
690-P: Semaglutide in Patients with Type 2 Diabetes: Real-World Data from Spain
Material Type:
Article
Add to My Research

690-P: Semaglutide in Patients with Type 2 Diabetes: Real-World Data from Spain

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1) [Peer Reviewed Journal]

Copyright American Diabetes Association Jun 1, 2021 ;ISSN: 0012-1797 ;EISSN: 1939-327X ;DOI: 10.2337/db21-690-P

Full text available

2
884-P: Health Care Experiences among People with Type 2 Diabetes: Identifying Social Determinants and Areas to Improve
Material Type:
Article
Add to My Research

884-P: Health Care Experiences among People with Type 2 Diabetes: Identifying Social Determinants and Areas to Improve

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1) [Peer Reviewed Journal]

Copyright American Diabetes Association Jun 1, 2021 ;ISSN: 0012-1797 ;EISSN: 1939-327X ;DOI: 10.2337/db21-884-P

Full text available

3
SPECIAL PODCAST: MANAGEMENT OF HYPERGLYCEMIA IN TYPE 2 DIABETES
Material Type:
Article
Add to My Research

SPECIAL PODCAST: MANAGEMENT OF HYPERGLYCEMIA IN TYPE 2 DIABETES

Diabetes (New York, N.Y.), 2023-02, Vol.72 (2), p.310 [Peer Reviewed Journal]

Copyright American Diabetes Association Feb 2023 ;ISSN: 0012-1797 ;EISSN: 1939-327X

Full text available

4
Special Podcast: Management of Hyperglycemia in Type 2 Diabetes
Material Type:
Article
Add to My Research

Special Podcast: Management of Hyperglycemia in Type 2 Diabetes

Diabetes care, 2023-01, Vol.46 (1), p.223 [Peer Reviewed Journal]

Copyright American Diabetes Association Jan 2023 ;ISSN: 0149-5992 ;EISSN: 1935-5548 ;DOI: 10.2337/dc23-ie01

Full text available

5
Unveiling the optimal soluble dietary fiber for type 2 diabetes: galactomannans take the lead?\Reply to Zurbau et al
Material Type:
Article
Add to My Research

Unveiling the optimal soluble dietary fiber for type 2 diabetes: galactomannans take the lead?\Reply to Zurbau et al

The American journal of clinical nutrition, 2023-10, Vol.118 (4), p.834 [Peer Reviewed Journal]

Copyright American Society for Clinical Nutrition, Inc. Oct 2023 ;ISSN: 0002-9165 ;EISSN: 1938-3207 ;DOI: 10.1016/j.ajcnut.2023.06.021

Full text available

6
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Material Type:
Article
Add to My Research

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Diabetes care, 2022-11, Vol.45 (11), p.2753-2786 [Peer Reviewed Journal]

2022 by the American Diabetes Association and the European Association for the Study of Diabetes. ;Copyright American Diabetes Association Nov 2022 ;2022 by the American Diabetes Association and the European Association for the Study of Diabetes 2022 ;ISSN: 0149-5992 ;EISSN: 1935-5548 ;DOI: 10.2337/dci22-0034 ;PMID: 36148880

Full text available

7
The burden and risks of emerging complications of diabetes mellitus
Material Type:
Article
Add to My Research

The burden and risks of emerging complications of diabetes mellitus

Nature reviews. Endocrinology, 2022-09, Vol.18 (9), p.525-539 [Peer Reviewed Journal]

2022. Springer Nature Limited. ;Springer Nature Limited 2022. ;Springer Nature Limited 2022 ;ISSN: 1759-5029 ;EISSN: 1759-5037 ;DOI: 10.1038/s41574-022-00690-7 ;PMID: 35668219

Full text available

8
Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes
Material Type:
Article
Add to My Research

Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes

Diabetes care, 2018-11, Vol.41 (11), p.2370-2376 [Peer Reviewed Journal]

2018 by the American Diabetes Association. ;Copyright American Diabetes Association Nov 1, 2018 ;ISSN: 0149-5992 ;EISSN: 1935-5548 ;DOI: 10.2337/dc18-1131 ;PMID: 30201847

Full text available

9
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Material Type:
Article
Add to My Research

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

The New England journal of medicine, 2020-10, Vol.383 (15), p.1425-1435 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2004967

Full text available

10
Diabetes knowledge predicts HbA1c levels of people with type 2 diabetes mellitus in rural China: a ten-month follow-up study
Material Type:
Article
Add to My Research

Diabetes knowledge predicts HbA1c levels of people with type 2 diabetes mellitus in rural China: a ten-month follow-up study

Scientific reports, 2023-10, Vol.13 (1), p.18248-18248, Article 18248 [Peer Reviewed Journal]

The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Springer Nature Limited 2023 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-023-45312-y ;PMID: 37880376

Full text available

11
992-P: Patient-Reported Outcomes for 2,335 Adults with Type 2 Diabetes Using the Omnipod Insulin Management System Show Glycemic Improvement over First 90 Days of Use
Material Type:
Article
Add to My Research

992-P: Patient-Reported Outcomes for 2,335 Adults with Type 2 Diabetes Using the Omnipod Insulin Management System Show Glycemic Improvement over First 90 Days of Use

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1) [Peer Reviewed Journal]

Copyright American Diabetes Association Jun 1, 2020 ;ISSN: 0012-1797 ;EISSN: 1939-327X ;DOI: 10.2337/db20-992-P

Full text available

12
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Material Type:
Article
Add to My Research

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

Diabetes care, 2019-12, Vol.42 (12), p.2272-2281 [Peer Reviewed Journal]

Copyright American Diabetes Association Dec 1, 2019 ;ISSN: 0149-5992 ;EISSN: 1935-5548 ;DOI: 10.2337/dc19-0883

Full text available

13
Comment on Park et al. U-Shaped Associations Between Body Weight Changes and Major Cardiovascular Events in Type 2 Diabetes Mellitus: A Longitudinal Follow-up Study of a Nationwide Cohort of Over 1.5 Million. Diabetes Care 2022;45:1239–1246 / Reply
Material Type:
Article
Add to My Research

Comment on Park et al. U-Shaped Associations Between Body Weight Changes and Major Cardiovascular Events in Type 2 Diabetes Mellitus: A Longitudinal Follow-up Study of a Nationwide Cohort of Over 1.5 Million. Diabetes Care 2022;45:1239–1246 / Reply

Diabetes care, 2022-12, Vol.45 (12), p.e187 [Peer Reviewed Journal]

Copyright American Diabetes Association Dec 2022 ;ISSN: 0149-5992 ;EISSN: 1935-5548 ;DOI: 10.2337/dc22-1495

Full text available

14
Gut microbiota in human metabolic health and disease
Material Type:
Article
Add to My Research

Gut microbiota in human metabolic health and disease

Nature reviews. Microbiology, 2021-01, Vol.19 (1), p.55-71 [Peer Reviewed Journal]

COPYRIGHT 2021 Nature Publishing Group ;Springer Nature Limited 2020. ;ISSN: 1740-1526 ;EISSN: 1740-1534 ;DOI: 10.1038/s41579-020-0433-9 ;PMID: 32887946

Full text available

15
Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030
Material Type:
Article
Add to My Research

Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030

Journal of hepatology, 2018-10 [Peer Reviewed Journal]

cc by-nc-nd (c) European Association for the Study of the Liver, 2018 info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-nd/3.0/es/ ;ISSN: 0168-8278 ;EISSN: 1600-0641 ;DOI: 10.1016/j.jhep.2018.05.036

Digital Resources/Online E-Resources

16
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Material Type:
Article
Add to My Research

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

The Lancet (British edition), 2021-07, Vol.398 (10295), p.143-155 [Peer Reviewed Journal]

2021 Elsevier Ltd ;2021. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)01324-6

Full text available

17
Erratum. Patients With Type 2 Diabetes Have an Increased Demand for Pacemaker Treatment: A Comparison With Age- and Sex-Matched Control Subjects From the General Population. Diabetes Care 2020;44:2853-2858
Material Type:
Article
Add to My Research

Erratum. Patients With Type 2 Diabetes Have an Increased Demand for Pacemaker Treatment: A Comparison With Age- and Sex-Matched Control Subjects From the General Population. Diabetes Care 2020;44:2853-2858

Diabetes care, 2022-10, Vol.45 (10), p.2476-2476 [Peer Reviewed Journal]

Copyright American Diabetes Association Oct 2022 ;2022 by the American Diabetes Association 2022 ;ISSN: 0149-5992 ;EISSN: 1935-5548 ;DOI: 10.2337/dc22-er10 ;PMID: 35947727

Full text available

18
Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes
Material Type:
Article
Add to My Research

Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes

Diabetes care, 2021-08, Vol.44 (10), p.2438-2444 [Peer Reviewed Journal]

2021 by the American Diabetes Association. ;Copyright American Diabetes Association Oct 1, 2021 ;2021 by the American Diabetes Association 2021 ;ISSN: 0149-5992 ;EISSN: 1935-5548 ;DOI: 10.2337/dci21-0034 ;PMID: 34462270

Full text available

19
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Material Type:
Article
Add to My Research

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

The Lancet (British edition), 2021-03, Vol.397 (10278), p.971-984 [Peer Reviewed Journal]

2021 Elsevier Ltd ;Copyright © 2021 Elsevier Ltd. All rights reserved. ;2021. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(21)00213-0 ;PMID: 33667417

Full text available

20
Diabetes in China: Epidemiology and Genetic Risk Factors and Their Clinical Utility in Personalized Medication
Material Type:
Article
Add to My Research

Diabetes in China: Epidemiology and Genetic Risk Factors and Their Clinical Utility in Personalized Medication

Diabetes (New York, N.Y.), 2018-01, Vol.67 (1), p.3-11 [Peer Reviewed Journal]

2017 by the American Diabetes Association. ;Copyright American Diabetes Association Jan 1, 2018 ;ISSN: 0012-1797 ;EISSN: 1939-327X ;DOI: 10.2337/dbi17-0013 ;PMID: 29263166

Full text available

Results 1 - 20 of 26,709  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (25,484)

Refine My Results

Creation Date 

From To
  1. Before 1989  (9)
  2. 1989 To 1996  (43)
  3. 1997 To 2004  (217)
  4. 2005 To 2013  (1,025)
  5. After 2013  (25,420)
  6. More options open sub menu

Subject 

  1. Diabetes Mellitus  (26,617)
  2. Diabetes  (21,940)
  3. Science & Technology  (20,969)
  4. Life Sciences & Biomedicine  (18,136)
  5. Humans  (11,867)
  6. Type 2 Diabetes  (9,239)
  7. Glucose  (9,200)
  8. Insulin  (9,042)
  9. Male  (6,714)
  10. Risk Factors  (6,480)
  11. Endocrinology & Metabolism  (6,420)
  12. Female  (6,269)
  13. Insulin Resistance  (5,952)
  14. Patients  (5,612)
  15. Metabolism  (5,375)
  16. Obesity  (5,171)
  17. Middle Aged  (4,889)
  18. Cardiovascular Diseases  (4,354)
  19. Body Mass Index  (4,125)
  20. Adult  (3,589)
  21. More options open sub menu

Language 

  1. English  (26,495)
  2. Japanese  (2,085)
  3. German  (147)
  4. Norwegian  (52)
  5. Spanish  (49)
  6. Portuguese  (48)
  7. Polish  (14)
  8. Chinese  (12)
  9. Dutch  (8)
  10. Russian  (7)
  11. Turkish  (5)
  12. French  (3)
  13. Italian  (3)
  14. Slovak  (1)
  15. Lithuanian  (1)
  16. Hungarian  (1)
  17. Czech  (1)
  18. Croatian  (1)
  19. Swedish  (1)
  20. Danish  (1)
  21. More options open sub menu

Searching Remote Databases, Please Wait